

The effects of chitosan-based materials on glioma: Recent advances in its applications for diagnosis and treatment

Masoumeh Eslahi, Parisa Maleki Dana, Zatollah Asemi, Jamal Hallajzadeh, Mohammad Ali Mansournia, Bahman Yousefi



PII: S0141-8130(20)35117-5

DOI: <https://doi.org/10.1016/j.ijbiomac.2020.11.180>

Reference: BIOMAC 17343

To appear in: *International Journal of Biological Macromolecules*

Received date: 14 March 2020

Revised date: 5 July 2020

Accepted date: 25 November 2020

Please cite this article as: M. Eslahi, P.M. Dana, Z. Asemi, et al., The effects of chitosan-based materials on glioma: Recent advances in its applications for diagnosis and treatment, *International Journal of Biological Macromolecules* (2018), <https://doi.org/10.1016/j.ijbiomac.2020.11.180>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The effects of chitosan-based materials on glioma: Recent advances in its applications for diagnosis and treatment

Masoumeh Eslahi¹, Parisa Maleki Dana¹, Zatollah Asemi¹, Jamal Hallajzadeh^{2*}, Mohammad Ali Mansournia³, Bahman Yousefi^{4**}

¹ *Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, I.R. Iran*

² *Department of Biochemistry and Nutrition, Research Center for Evidence-Based Health Management, Maragheh University of Medical Sciences, Maragheh, Iran*

³ *Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran*

⁴ *Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran*

Running Title: Chitosan and glioma

* Corresponding Author: Jamal Hallajzadeh, PhD.

** Corresponding Author. Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. E-mail addresses: bahmanusefi@gmail.com (Bahman Yousefi).

The co-authors' email addresses:

1. Masoumeh Eslahi

masoumeheslahi@gmail.com

2. Parisa Maleki Dana

prs.maleki@yahoo.com

3. Zatollah Asemi

Asemi_r@yahoo.com

4. Jamal Hallajzadeh

jamal.hallaj@yahoo.com

5. Mohammad Ali Mansournia

mansournia_ma@yahoo.com

6. Bahman Yousefi

bahmanusefi@gmail.com

Number of words (Text): 3214

Number of words (Abstract): 254

Number of Figures: 1

Abstract

Glioma is known as the most common primary brain tumor occurring in adolescents and is considered as a lethal disease worldwide. Despite the advancements in presently available therapeutic approaches (i.e. radiation therapy and chemotherapy), the rate of amelioration in glioma patients is still low. In this regard, it seems that there is a need for reconsidering and enhancing current therapies and/or discovering novel therapeutic platforms. Chitosan is a natural polysaccharide with several beneficial characteristics, including biocompatibility, biodegradability, and low toxicity. Without causing toxic effects on healthy cells, chitosan nanoparticles are attractive targets in cancer therapy which lead to the sustained release and enhanced internalization of chemotherapeutic drugs as well as higher cytotoxicity for cancer cells. Hence, these properties turn it into a suitable candidate for the treatment of various cancers, including glioma. In the viewpoint of glioma, cancer inhibition is possible through targeting glioma-associated signaling pathways and molecules such as MMP-9, VEGF, TRAIL and nuclear factor- κ B by chitosan and its derivatives. Moreover, it has been acknowledged that chitosan and its derivatives can be applied as a delivery system for carrying a diverse range of therapeutic agents to the tumor site. Besides the anti-glioma effects of chitosan and its derivatives, these molecules can be utilized for culturing glioma cancer cells; providing a better understanding of glioma pathogenesis. Furthermore, it is documented that 3D chitosan scaffolds are potential targets that offer advantageous drug screening platforms. Herein, we summarized the anti-glioma effects of chitosan and also its utilization as drug delivery systems in the treatment of glioma.

Keywords: Chitosan, glioma, drug delivery, scaffold, cell culture

1. Glioma

Annually, 27,000 new cases of malignant glial tumors and 1000 new cases of malignant ependymal tumors are diagnosed as glioma, according to Europe guidelines which are provided for the diagnosis, prognosis, and treatment of the most common adult brain tumors [1]. Indeed, one of the most life-threatening types of adult brain tumor is glioblastoma multiforme (GBM) which is accounted for about 80% of all primary malignant central nervous system (CNS) tumors [2, 3]. GBM and anaplastic glioma are the most frequent glial tumors, comprising more than 50% and 10% of the total glioma, respectively [4]. Several risk factors are related to the incidence of GBM. Among them, age is associated with a higher incidence and mortality rate in GBM. The average age of diagnosed patients is 64 years old [5]. Moreover, the incidence of GBM is lower in women compared to men [6].

While glioma is mainly the most frequent intrinsic CNS tumor, it inclines to develop metastatic forms and represents poor response to chemotherapy and radiotherapy with undesirable outcomes [7]. Gliomas encompass two principal subgroups: Diffuse glioma is one of the subgroups of glioma that is defined by wide-ranging infiltrative growth into the surrounding parenchyma of CNS. Non-diffuse glioma is another subtype that shows a more circumscribed growth pattern that is characterized by pilocytic astrocytoma and ependymomas, which are rather common signs of this subgroup [8]. Despite the extensive efforts that have been made internationally in clinical oncology, treatment of GBM is still challenging [9-11]. At present, the mainstay of treatment for glioma is surgical resection followed by concurrent chemotherapy and radiotherapy. The treatment of patients with gliomas, particularly GBM, has been improved greatly through the mentioned treatments. However, the results of these treatments are not

promising. Common anticancer therapies may lead to drug resistance and subsequent recurrence or metastasis of cancer. The median survival time of patients diagnosed with GBM ranges from 12 to 15 months; meanwhile, the 5-year survival rate has been less than 5% [12]. Therefore, new treating strategies are essential to combat glioma and improve the survival rates of patients who suffer from glioma.

2. Risk factors of glioma

Exposure to a high dose of ionizing radiation is the only confirmed risk factor of GBM up to now [13-15]. Radiation exposure accounted for more than 116 cases of GBM which have been reported since the 1960s. It has been estimated that the overall risk of developing GBM after radiation therapy is 2.5% [16]. Findings of experimental animal studies have shown that some pesticides and other agricultural chemicals, such as organochlorides and alkylureas combined with copper sulfates are capable of inducing cancer, as well. However, case-control and cohort studies of agricultural workers have reported equal negative or positive findings related to the risk for brain tumors [17]. A meta-analysis has shown that taking vitamin C may reduce the risk of glioma [18]. Few studies have shown that ovarian steroid hormones play a possible role in the development of GBM [19]. Also, it is reported that long-term consumption of hormonal contraceptives may lead to a higher risk of glioma [20]. Occupational risk factors, severe head injury, exposure to the pesticide, smoking, dietary risk factors, cell phones, and electromagnetic field are environmental factors that have no conclusive association with GBM [13, 15, 21-23]. However, studies indicated that average amounts of weekly exposure to carbon tetrachloride have been related to a higher risk of glioma in people who are occupationally exposed to it [24]. Nelson et al. also reported that occupational exposure to carbon tetrachloride and sugar intake

are two risk factors for the development of glioma [25]. Some investigations reported that diabetes mellitus is inversely associated with the risk of glioma [26-28]. Zhao et al. [29] also demonstrated that there is an association between diabetes mellitus and reduced risk of glioma. Besides, they reported that males and Caucasians with diabetes mellitus have a lower risk of glioma [29]. Based on some studies, the effect of infection and allergic diseases on GBM is possibly protective, which may due to the initiation of immune surveillance mechanism [14, 23]. A study has shown that the risk of developing glioma is reduced by 40% in people who suffer from allergies [30]. Also, gliomas are found to run in families but its susceptibility gene has not been identified yet [14]. Reports indicated that the incidence of some specific subtypes of glioma can be increased by inherited monogenic Mendelian syndromes such as Li-Fraumeni syndrome and Lynch syndrome, which are associated with GBM. Tuberous sclerosis, neurofibromatosis type 1 and type 2 are also related to multiple types of glioma including giant cell astrocytoma, astrocytoma, optic nerve glioma, and ependymoma. Furthermore, Ollier disease (Maffucci syndrome) and melanoma-neural system tumor syndrome have been reported to be involved in the incidence of all gliomas [21]. GBM shows a high degree of both genomic and spatial heterogeneity [32]. Changes in some genes are highly associated with GBM including RB1, TP53, NF1, PTEN, IDH1, EGFR, PIK3R1, and PIK3CA [33-35]. Additionally, patients with mutations in their L2HGDH gene, which leads to L-2-hydroxyglutaric aciduria, have been observed to have a higher incidence of brain tumors [32]. IDH1 mutation is observed to be present in several secondary GBM. Whereas, evidence expressed that it is not present in primary GBM. Neomorphic enzymatic activity of IDH1 results in the generation of 2-hydroxyglutarate that is an oncometabolite. 2-hydroxyglutarate production leads to some cell function alterations which relate it to epigenome and development of GBM [36]. Gene mutation is also able to alter

some signaling pathways such as dysregulation of growth factors, inactivation of Rb and p53, and activation of phosphoinositide 3-kinase; thereby, participate in GBM pathogenesis [32].

3. Chitin and its derivative

Chitin, poly (β -(1–4)-poly-N-acetyl-D-glucosamine), is a biopolymer that is synthesized by several organisms [37]. After cellulose, it is the second most abundant polysaccharide that is widely distributed in nature. Chitin is the main structural compound in the cell wall of fungi and exoskeleton of crustaceans, such as crabs and shrimps. Chitin is found in nature as ordered microfibrils. Chitin is only usable in the field of biomedicine after converting to its derivatives, especially chitosan. [38]. Both chitin and chitosan are biocompatible, biodegradable, and non-toxic biopolymers. Also, they have antimicrobial and hydrating effects. Furthermore, chitosan, along with other molecules, is used to culture cancer cells [39]. Because of these unique properties, chitosan has recently received considerable attention in the biomedical field [40].

4. Roles of chitosan in biological processes

Chitosan has various biological benefits, including antimicrobial [41], anti-tumor [42], and immune-promoting activities. Studies have shown that chitosan can increase IL-2-mediated expansion of leukocytes in tumors and tumor-draining lymph nodes by 40% and 100%, respectively. Immuno-phenotyping studies demonstrated that chitosan co-formulation causes an increase in the IL-12-induced populations of important effectors, such as CD8+IFN- γ + and NKT cells, in tumors and dendritic cell populations of the tumor-draining lymph nodes [42]. Chitin and chitosan oligosaccharides can regulate the inflammatory activities in macrophages [43]. Moreover, chitosan promotes dendritic cell maturation by inducing type I interferons (IFNs) and

enhances antigen-specific T helper 1 (Th1) responses in a type I IFN receptor-dependent manner [44]. In gingival fibroblasts, chitosan has shown an anti-inflammatory activity *via* reducing the production of prostaglandin E-2 (PGE-2) through downregulating the c-Jun N-terminal kinase (JNK) signaling pathway. Also, chitosan suppresses the adipogenesis in 3T3-L1 adipocytes. However, the effect of chitosan molecular weight on inflammatory activity is still questionable for researchers and some reverse effects have been observed [45].

5. Anti-tumor activities of chitosan

Novel studies indicate that there are certain subpopulations of cancer cells in a tumor from which the tumor can originate. These cells, which are called cancer stem cells (CSCs), have multiple similar characteristics to stem cells [46, 47]. These cells have been shown some features, including a higher ability of migration that is associated with invasion and metastasis [48]. Besides, they remain at a slow-cycling/quiescent state, which leads to resistance against anti-proliferative drugs [49]. Some certain surface markers such as CD133, EpCAM, and CD44 can be used for CSC identification and isolation [50]. CSCs have the ability of self-renewal that provides maintenance of CSC pools as well as differentiation into heterogeneous progeny cancer cells [51]. Signaling cascades within CSCs, such as Notch, STAT3, and Wnt/ β -catenin, to are not regulated to maintain their stem cell properties [52]. Hence, targeting CSCs and some specific signaling pathways which are essential for tumor cells can provide novel and promising therapeutic strategies [55]. Chitosan cross-linked with other molecules is being used for culturing cancer cells [39, 56]. For instance, the CD133⁺ GBM CSC population may be enriched by porous chitosan-alginate scaffolds [57]. Also, breast cancer stemness may be increased by electrospun polycaprolactone-chitosan scaffolds [58]. However, the mechanisms of interactions

between cells and biomaterials are not yet well-known. Some investigations indicated that chitosan membranes and hyaluronan (HA) grafted chitosan (CSHA) membranes could increase the stemness of mesenchymal stem cells (MSCs) [59]. The main ligand of CD44 receptor that is aberrantly expressed on the surface of CSCs is HA [60]. Likely through the interaction of HA and CD44 receptor, CSHA membranes promote the aggressiveness of lung cancer cells. However, the influence of chitosan itself on some cancer cells remains to be elucidated [61]. In a recent study by Rao et al. it is demonstrated that chitosan nanoparticles could bind to CSCs via CD44 receptor, a major target gene of Wnt signaling [62, 63]. This finding indicated that the chemical properties of chitosan are somehow similar to HA.

Chang et al. [64] recently demonstrated that chitosan itself enhances the CSC-related characteristics and tumor progression of not only CD44^{positive} colon cancer cells but also CD44^{negative} HCC cells. They observed that chitosan alone could increase cancer cell stemness properties and tumor progression. Meanwhile, they showed that chitosan and CSHA could induce diverse morphology in various cancer cells [64]. Several studies have been revealed that SW480 cells are not able to form spheroids and they fail to aggregate on chitosan and CSHA. HT29, DLD-1 and HCT116 are all CD44-positive cells which can aggregate on CSHA membranes [64-66]. Thus, chitosan as a suitable platform that has similar properties with ECM may be useful for studies concerning CSC biology as well as drug screening.

6. Application of chitosan as a drug delivery system for glioma

As we mentioned earlier, chitosan is a biodegradable and biocompatible agent which is used in the pharmaceutical industry. Within the past two decades, chitosan has been used for delivering

various therapeutic agents in nanoparticle forms [69]. There are several methods for preparing chitosan nanoparticles, such as emulsion solvent diffusion, nanoprecipitation, and emulsion cross-linking [69]. Utilization of nanomaterial-based drugs is associated with various advantages i.e., targeting drug to specific sites in the body, enhanced bioavailability by improving aqueous solubility, increasing residence time in the body and passing the blood-brain barrier [70]. Recently, findings have shown that a combination of chitosan and nanotechnology may lead to overcoming the challenges we are currently facing in delivering drugs [70]. Herein, we take a look into recent studies concerning with chitosan-based drug delivery systems that are used for treating glioma.

Chitosan-coated poly(lactide-co-glycolic acid) nanoparticles that are modified with polyethylene glycol and loaded with paclitaxel and R-flurbiprofen have shown efficient delivery of drugs to the tumor site. Moreover, these nanoparticles have higher cytotoxic effects against glioma due to the combination of anti-inflammatory and antitumor agents [71]. In C6 glioma cells, silibinin-loaded chitosan nanoparticles provide sustained release of the drugs while increasing the expression levels of Bax and caspase3, two essential parts of apoptosis [72]. Turabee et al. [73] found that hydrogel of N, N, N trimethyl chitosan combined with pluronic F127 provides a sustained release of docetaxel. In GBM cells, this delivery method has a more effective killing ability than free docetaxel or docetaxel-loaded pluronic F127 [73]. Another study showed that chitosan coating changes the surface charge of core-shell polymeric nanoparticles to positive values, which enhances the nanoparticles internalization [74]. Besides, these nanoparticles that were loaded with docetaxel have shown higher cytotoxicity in comparison with docetaxel alone [74]. Poly-L-arginine-chitosan-triphosphate matrix nanoparticle loaded with doxorubicin and superparamagnetic iron oxide is a potential delivery system for diagnostic and therapeutic

purposes in GBM [75]. It is revealed that increasing the concentration of iron that is used in this method results in a decline in times of T_2 relaxation of MRI [75]. Chitosan-capped gold nanoparticles have been shown to cause selective cytotoxicity for GBM stem cells without affecting normal cells [76]. Unlike uncoated nanoparticles, nanoparticles composed of chitosan exhibit a high accumulation in cells within the lysosomes and cytosol as well as near the nucleus [76]. Sharma et al. [77] designed a nanoformulation consisted of polyamidoamine dendrimer and chitosan for delivering temozolomide to GBM. They reported that this delivery method is more efficient than temozolomide alone since the concentration of the drug was doubled in the brain with this method [77]. Chitosan nanoparticles with an outer shell of 1,3 β -Glucan have been used for delivering paclitaxel to malignant GBM [78]. Findings showed that this platform provides multiple benefits including improved drug bioavailability, overcoming systemic toxicity, decreasing hemolytic properties, and more cytotoxicity against glioma cancer cells [78].

7. Application of chitosan in culturing glioma cells to study the biology of these cells and develop therapies

Despite the ability of patient-derived xenografts of GBM that provide a similar behavior as an *in vivo* tumor characteristic, these xenografts are reported to be costly and time-consuming [79]. In the other hand, testing potential anti-tumor agents require *in vitro* models which provide a suitable microenvironment for glioma [80]. Furthermore, pre-clinical studies of drug screening that use 2D culturing methods are not much effective in patients [81]. Chitosan is an excellent candidate biomaterial for designing scaffolds, which enhances tissue regeneration and tissue engineering [82].

It is reported that 3D chitosan-alginate scaffold can be used as a beneficial microenvironment for glioma since human glioma cells exhibit higher malignancy when they are cultured in chitosan-alginate scaffolds [83]. This report showed that chitosan scaffolds, which have properties similar to the extracellular matrix, provide an environment for glioma cells to show a phenotype more similar to *in vivo* condition [83]. A study showed that culturing GBM cells on chitosan-polycaprolactone polyblend nanofibers results in an upregulation of genes related to invasiveness, such as Twist, STAT3, Snail, β -catenin, and TGF- β [80]. Moreover, the cultured cells present the same migration profile as *in vivo* cells [80]. Chitosan and HA have been used for synthesizing a 3D scaffold [84]. While monolayer and flat epithelioid cells are grown in 2D adherent cultures, GBM cells have been observed to form ovoid cells clusters in the pores of chitosan-hyaluronic acid scaffolds [84]. Besides, cells that grow on these scaffolds indicated remarkable features, including higher expression levels of genes related to EMT, exhibiting an undifferentiated phenotype, and higher expression levels of genes related to hypoxia-induced oxidative stress [84]. It is found that chitosan and chitosan-hyaluronic acid scaffolds can form glioma cell spheroids [85]. Scaffold-grown cells present a higher expression of biomarkers associated with glioma stem cells in comparison with common 2D monolayers [85]. Noteworthy, cells that were cultured on chitosan-HA scaffold have a higher ability of tumorigenicity *in vivo* compared to 2D-cultured cells [85]. HIF-1 α , Nestin, Musashi-1, GFAP, and CD44 which are stem-like characteristics of GBM cells have been observed to be upregulated in chitosan-HA scaffolds compared with 2D-cultured cells [81]. Besides, 3D-cultured cells showed higher resistance to chemotherapeutic drugs [81].

8. Possible effects of chitosan on signaling pathways involved in glioma

Studies reported that some signaling pathways are involved in the pathogenesis and development of glioma. Chitosan has been observed to have a beneficial effect in the treatment of cancer cells *via* involving different signaling pathways [86-88]. Herein, we investigate the possible effects of chitosan on some signaling pathways that are involved in glioma. However, the exact roles of chitosan in glioma signaling pathways are remained to be elucidated.

Various factors contribute to the regulation of signaling pathway and maintenance of GBM malignant cells such as increased metabolism rate and reactive oxygen species (ROS) [89]. ROS activates the transcription factor nuclear factor- κ B (NF- κ B). Subsequently, NF- κ B activates the expression of genes involved in tumor growth and development [90]. Formation of amyloid β , which is induced by oxidative stress, and cytotoxicity are prevented by chitosan in NT2 neurons. This prevention occurs through two transcription factors: NF- κ B and Nrf2. Hence, chitosan might be considered as an additional therapeutic strategy to combat neural demise in Alzheimer's disease as well as other diseases that are associated with oxidative stress. Therefore, chitosan has the potential to be used for both preventing and treating diseases of CNS [91]. Interestingly, inhibiting the NF- κ B reduces matrix metalloproteinase-2 (MMP-2) and MMP-9 expression [90]. MMPs are enzymes that have various roles in the destruction of the extracellular matrix and serve as important factors in physiological and malignant processes [92]. Based on the evidence, the upregulation of MMP expression is a critical cause of tumor growth and inhibition of anti-tumor processes [93]. Current studies approved the nutraceutical value of two water-soluble derivatives of chitosan and chitin, carboxymethyl-chitosan and carboxymethyl-chitin. These derivatives serve as potent antioxidants and MMP inhibitor; leading to the alleviations of radical-induced oxidative damage [94]. Chitosan polymer has also been used for

delivering a bioactive compound with neuroprotective effects, eugenol, to glioma cells. Findings showed that eugenol-loaded chitosan is capable of the inhibiting protein expression of NF- κ B as well as reducing MMP-9 and urokinase-type plasminogen activator. Moreover, this nanopolymer significantly decreased the expression of VEGF [95]. Human tumor necrosis factor α - related apoptosis- inducing ligand (TRAIL) is one of the TNF cytokine superfamily members. TRAIL forms a homotrimer that crosslinks death receptors on the cell surface; resulting in downstream signaling of apoptosis [96, 97]. While the majority of GBM express death receptors [98], studies have shown that TRAIL can be a potential target for glioma treatment [99]. Wang et al. [100] designed an iron oxide nanoparticle coated with chitosan–polyethylene glycol–polyethyleneimine copolymer and chlorotoxin to provide a delivery system of plasmid DNA encoding TRAIL into GBM. They observed that TRAIL was successfully delivered into human T98G GBM cells. The results suggested that this drug delivery system is a potential candidate to combat against GBM [100].

9. Conclusions

Considering statistics, the high rate of mortality, and the low life quality of glioma patients, it seems that common therapies are not satisfying enough. Besides, there are several challenges in the study of the glioma cells as well as developing new therapies for this cancer. Chitosan, which has been used against various cancers, has recently attracted the attention of glioma-related researches. Chitosan nanoparticles have been suggested to have anti-tumor characteristics against glioma cells as evidenced by their effects on several signaling pathways and molecules. A variety of glioma chemotherapeutic drugs has been loaded into chitosan nanoparticles. These nanoparticles are reported to be more effective than pure therapeutic drugs due to multiple

features, including the sustained release of the drug, enhanced internalization of the drug, and higher cytotoxicity on cancer cells. Since 2D-cultured cells have different characteristics from the cells grown *in vivo*, this culturing method is not much effective for screening drugs. Findings demonstrate that 3D chitosan scaffolds are potential targets for providing a drug screening platform (**Fig.1**). Moreover, culturing glioma cells on chitosan-based scaffolds leads to a better understanding of glioma stem cell biology. Altogether, we believe chitosan is a promising agent that can be used as a sufficient drug delivery system for treatment of glioma as well as circumventing obstacles existing in the studying of the glioma cells and drug screening.

Abbreviations

Declarations

Acknowledgements

The Authors would like to thanks Clinical Research Development Unit, Shohada Hospital, Tabriz University of Medical Sciences for kind supports.

Funding

Not applicable.

Availability of data and material

Not applicable.

Author contributions

ME, ZA and BY contributed in conception, design and drafting of the manuscript. PMD, JH and MAM contributed in data collection and manuscript drafting. All authors approved the final version for submission.

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no conflict of interest.

References

1. Khani, P., et al., Genetic and epigenetic contribution to astrocytic gliomas pathogenesis. 2019. **148**(2): p. 188-203.
2. Bush, N.A.O., S.M. Chang, and M.S. Berger, Current and future strategies for treatment of glioma. *Neurosurgical review*, 2017. **40**(1): p. 1-14.
3. Masoudi, M.S., E. Mehrabian, and H. Mirzaei, MiR-21: A key player in glioblastoma pathogenesis. 2018. **119**(2): p. 1285-1290.
4. Reni, M., et al., Central nervous system gliomas. *Critical reviews in oncology/hematology*, 2017. **113**: p. 213-234.
5. Ladomersky, E., et al., The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma. *Front Pharmacol*, 2019. **10**: p. 200.
6. Thakkar, J.P., et al., Epidemiologic and molecular prognostic review of glioblastoma. *Cancer Epidemiology and Prevention Biomarkers*, 2014. **23**(10): p. 1985-1996.
7. Guan, N., et al., Long non-coding RNA linc0119 regulates the development of gliomas through the Wnt/ β -catenin signaling pathway. *European review for medical and pharmacological sciences*, 2019. **23**(10): p. 4243-4253.
8. Wesseling, P. and D. Capper, WHO 2016 classification of gliomas. *Neuropathology and applied neurobiology*, 2018. **44**(2): p. 139-150.
9. Mrugala, M.M., Advances and challenges in the treatment of glioblastoma: a clinician's perspective. *Discovery medicine*, 2013. **15**(83): p. 221-230.
10. Saadatpour, L., et al., Glioblastoma: exosome and microRNA as novel diagnosis biomarkers. *Cancer Gene Ther*, 2016. **23**(12): p. 415-418.
11. Shabaninejad, Z., et al., Therapeutic potentials of curcumin in the treatment of glioblastoma. *Eur J Med Chem*, 2020. **188**: p. 112040.
12. Binder, D.C., A.A. Davis, and D.A. Wainwright, Immunotherapy for cancer in the central nervous system: current and future directions. *Oncoimmunology*, 2016. **5**(2): p. e1082027.
13. Inskip, P.D., et al., Cellular-telephone use and brain tumors. *New England Journal of Medicine*, 2001. **344**(2): p. 79-86.
14. Bondy, M.L., et al., Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. *Cancer*, 2008. **113**(S7): p. 1953-1968.

15. Ohgaki, H., Epidemiology of brain tumors, in *Cancer Epidemiology*. 2009, Springer. p. 323-342.
16. Salvati, M., et al., Radiation-induced gliomas: report of 10 cases and review of the literature. *Surgical neurology*, 2003. **60**(1): p. 60-67.
17. Wrensch, M., et al., Epidemiology of primary brain tumors: current concepts and review of the literature. *Neuro-oncology*, 2002. **4**(4): p. 278-299.
18. Zhou, S., et al., Association between vitamin C intake and glioma risk: evidence from a meta-analysis. *Neuroepidemiology*, 2015. **44**(1): p. 39-44.
19. Kabat, G.C., A.M. Etgen, and T.E. Rohan, Do steroid hormones play a role in the etiology of glioma? *Cancer Epidemiology and Prevention Biomarkers*, 2010. **19**(10): p. 2421-2427.
20. Andersen, L., et al., Hormonal contraceptive use and risk of glioma among younger women: a nationwide case-control study. *Br J Clin Pharmacol*, 2015. **79**(4): p. 677-84.
21. Adamson, C., et al., Glioblastoma multiforme: a review of where we have been and where we are going. *Expert opinion on investigational drugs*, 2009. **18**(8): p. 1061-1083.
22. Agnihotri, S., et al., Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. *Archivum immunologiae et therapiae experimentalis*, 2013. **61**(1): p. 35-41.
23. Fisher, J.L., et al., Epidemiology of brain tumors. *Neurologic clinics*, 2007. **25**(4): p. 867-890.
24. Neta, G., et al., Occupational exposure to chlorinated solvents and risks of glioma and meningioma in adults. *Occup Environ Med*, 2012. **69**(11): p. 793-801.
25. Nelson, J.S., et al., Potential risk factors for incident glioblastoma multiforme: the Honolulu Heart Program and Honolulu-Asia Aging Study. *J Neurooncol*, 2012. **109**(2): p. 315-21.
26. Cahoon, E.K., et al., Immune-related conditions and subsequent risk of brain cancer in a cohort of 4.5 million male US veterans. *Br J Cancer*, 2014. **110**(7): p. 1825-33.
27. Kitahara, C.M., et al., Personal history of diabetes, genetic susceptibility to diabetes, and risk of brain glioma: a pooled analysis of observational studies. *Cancer Epidemiol Biomarkers Prev*, 2014. **23**(1): p. 47-54.

28. Seliger, C., et al., Diabetes, use of antidiabetic drugs, and the risk of glioma. *Neuro Oncol*, 2016. **18**(3): p. 340-9.
29. Zhao, L., Z. Zheng, and P. Huang, Diabetes mellitus and the risk of glioma: a meta-analysis. *Oncotarget*, 2016. **7**(4): p. 4483-9.
30. Linos, E., et al., Atopy and risk of brain tumors: a meta-analysis. *Journal of the National Cancer Institute*, 2007. **99**(20): p. 1544-1550.
31. Ostrom, Q.T., et al., Epidemiology of Intracranial Gliomas. *Prog Neurol Surg*, 2018. **30**: p. 1-11.
32. Cahill, D. and S. Turcan, Origin of Gliomas. *Semin Neurol*, 2018. **38**(1): p. 5-10.
33. Cerami, E., et al., The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov*, 2012. **2**(5): p. 401-4.
34. Gao, J., et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal*, 2013. **6**(269): p. p11.
35. Lawrence, M.S., et al., Discovery and saturation analysis of cancer genes across 21 tumour types. *Nature*, 2014. **505**(7484): p. 495-501.
36. Liu, A., et al., Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation. *Front Oncol*, 2016. **6**: p. 16.
37. Elieh-Ali-Komi, D. and M.R. Faridol, Chitin and Chitosan: Production and Application of Versatile Biomedical Nanomaterials. *Int J Adv Res (Indore)*, 2016. **4**(3): p. 411-427.
38. Elieh-Ali-Komi, D. and M.R. Hamblin, Chitin and chitosan: production and application of versatile biomedical nanomaterials. *International journal of advanced research*, 2016. **4**(3): p. 411.
39. Shanmugasundaram, N., et al., Collagen–chitosan polymeric scaffolds for the in vitro culture of human epidermoid carcinoma cells. *Biomaterials*, 2001. **22**(14): p. 1943-1951.
40. Jayakumar, R., et al., Biomaterials based on chitin and chitosan in wound dressing applications. *Biotechnology advances*, 2011. **29**(3): p. 322-337.
41. Tavaría, F.K., et al., Influence of abiotic factors on the antimicrobial activity of chitosan. *The Journal of dermatology*, 2013. **40**(12): p. 1014-1019.
42. Yang, L. and D.A. Zaharoff, Role of chitosan co-formulation in enhancing interleukin-12 delivery and antitumor activity. *Biomaterials*, 2013. **34**(15): p. 3828-3836.

43. Chakrabarti, A., et al., Immunomodulation of macrophages by methylglyoxal conjugated with chitosan nanoparticles against Sarcoma-180 tumor in mice. *Cellular immunology*, 2014. **287**(1): p. 27-35.
44. Carroll, E.C., et al., The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type I interferons. *Immunity*, 2016. **44**(3): p. 597-608.
45. Chang, S.-H., et al., Effect of chitosan molecular weight on anti-inflammatory activity in the RAW 264.7 macrophage model. *International journal of biological macromolecules*, 2019. **131**: p. 167-175.
46. Ishizawa, K., et al., Tumor-initiating cells are rare in many human tumors. *Cell stem cell*, 2010. **7**(3): p. 279-282.
47. Clevers, H., The cancer stem cell: premises, promises and challenges. *Nature medicine*, 2011. **17**(3): p. 313.
48. Li, F., et al., Beyond tumorigenesis: cancer stem cells in metastasis. *Cell research*, 2007. **17**(1): p. 3-14.
49. Zeuner, A., et al., Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-X L inhibition in non-small cell lung cancer. *Cell Death & Differentiation*, 2014. **21**(12): p. 1877-1888.
50. Medema, J.P., Cancer stem cells: the challenges ahead. *Nature cell biology*, 2013. **15**(4): p. 338-344.
51. Wicha, M.S., Targeting self-renewal, an Achilles' heel of cancer stem cells. *Nature medicine*, 2014. **20**(1): p. 14.
52. Takebe, N., et al., Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. *Nature reviews Clinical oncology*, 2015. **12**(8): p. 445.
53. Vermeulen, L., et al., Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. *Nature cell biology*, 2010. **12**(5): p. 468-476.
54. Gujral, T.S., et al., A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. *Cell*, 2014. **159**(4): p. 844-856.
55. Vidal, S., et al., Targeting cancer stem cells to suppress acquired chemotherapy resistance. *Oncogene*, 2014. **33**(36): p. 4451-4463.

56. Florczyk, S.J., et al., 3D porous chitosan–alginate scaffolds: a new matrix for studying prostate cancer cell–lymphocyte interactions in vitro. *Advanced healthcare materials*, 2012. **1**(5): p. 590-599.
57. Kievit, F.M., et al., Proliferation and enrichment of CD133+ glioblastoma cancer stem cells on 3D chitosan-alginate scaffolds. *Biomaterials*, 2014. **35**(33): p. 9137-9143.
58. Sims-Mourtada, J., et al., Enrichment of breast cancer stem-like cells by growth on electrospun polycaprolactone-chitosan nanofiber scaffolds. *International journal of nanomedicine*, 2014. **9**: p. 995.
59. Huang, G.-S., et al., Spheroid formation of mesenchymal stem cells on chitosan and chitosan-hyaluronan membranes. *Biomaterials*, 2011. **32**(29): p. 6929-6945.
60. Zöller, M., CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? *Nature Reviews Cancer*, 2011. **11**(4): p. 254-267.
61. Huang, Y.-J. and S.-h. Hsu, Acquisition of epithelial–mesenchymal transition and cancer stem-like phenotypes within chitosan-hyaluronan membrane-derived 3D tumor spheroids. *Biomaterials*, 2014. **35**(38): p. 10070-10079.
62. Rao, W., et al., Chitosan-decorated doxorubicin-encapsulated nanoparticle targets and eliminates tumor reinitiating cancer stem-like cells. *ACS nano*, 2015. **9**(6): p. 5725-5740.
63. Wielenga, V.J., et al., Expression of CD44 in Apc and Tcfmutant mice implies regulation by the WNT pathway. *The American journal of pathology*, 1999. **154**(2): p. 515-523.
64. Chang, P.-H., et al., Chitosan promotes cancer progression and stem cell properties in association with Wnt signaling in colon and hepatocellular carcinoma cells. *Scientific reports*, 2017. **7**(1): p. 1-14.
65. Oshima, N., et al., Induction of cancer stem cell properties in colon cancer cells by defined factors. *PloS one*, 2014. **9**(7).
66. Leng, Z., et al., Krüppel-like factor 4 acts as an oncogene in colon cancer stem cell-enriched spheroid cells. *PloS one*, 2013. **8**(2).
67. Fletcher, J.I., et al., ABC transporters in cancer: more than just drug efflux pumps. *Nature Reviews Cancer*, 2010. **10**(2): p. 147-156.
68. Tanei, T., et al., Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. *Clinical cancer research*, 2009. **15**(12): p. 4234-4241.

69. Naskar, S., K. Koutsu, and S. Sharma, Chitosan-based nanoparticles as drug delivery systems: a review on two decades of research. *J Drug Target*, 2019. **27**(4): p. 379-393.
70. Li, J., et al., Chitosan-Based Nanomaterials for Drug Delivery. *Molecules*, 2018. **23**(10).
71. Caban-Toktas, S., et al., Combination of Paclitaxel and R-flurbiprofen loaded PLGA nanoparticles suppresses glioblastoma growth on systemic administration. *Int J Pharm*, 2020. **578**: p. 119076.
72. Alipour, M., et al., Sustained release of silibinin-loaded chitosan nanoparticle induced apoptosis in glioma cells. *J Biomed Mater Res A*, 2020. **108**(3): p. 458-469.
73. Turabee, M.H., et al., N,N,N-trimethyl chitosan embedded in situ Pluronic F127 hydrogel for the treatment of brain tumor. *Carbohydr Polym*, 2019. **20**: p. 302-309.
74. Varan, C. and E. Bilensoy, Cationic PEGylated polycaprolactone nanoparticles carrying post-operation docetaxel for glioma treatment. *Bull Stein J Nanotechnol*, 2017. **8**: p. 1446-1456.
75. Gholami, L., et al., Preparation of superparamagnetic iron oxide/doxorubicin loaded chitosan nanoparticles as a promising glioblastoma theranostic tool. *J Cell Physiol*, 2019. **234**(2): p. 1547-1559.
76. Aldea, M., et al., SChitosan-capped gold nanoparticles impair radioresistant glioblastoma stem-like cells. *J BUON*, 2018. **23**(3): p. 800-813.
77. Sharma, A.K., et al., Chitosan Engineered PAMAM Dendrimers as Nanoconstructs for the Enhanced Anti-Cancer Potential and Improved In vivo Brain Pharmacokinetics of Temozolomide. *Pharm Res*, 2018. **35**(1): p. 9.
78. Singh, P.K., et al., α , 1, 3beta-Glucan anchored, paclitaxel loaded chitosan nanocarrier endows enhanced biocompatibility with efficient anti-glioblastoma stem cells therapy. *Carbohydr Polym*, 2018. **180**: p. 365-375.
79. Stackhouse, C.T., et al., A Novel Assay for Profiling GBM Cancer Model Heterogeneity and Drug Screening. *Cells*, 2019. **8**(7).
80. Kievit, F.M., et al., Aligned chitosan-polycaprolactone polyblend nanofibers promote the migration of glioblastoma cells. *Adv Healthc Mater*, 2013. **2**(12): p. 1651-9.
81. Florczyk, S.J., et al., Porous chitosan-hyaluronic acid scaffolds as a mimic of glioblastoma microenvironment ECM. *Biomaterials*, 2013. **34**(38): p. 10143-50.

82. Martin-Lopez, E., M. Nieto-Diaz, and M. Nieto-Sampedro, Differential adhesiveness and neurite-promoting activity for neural cells of chitosan, gelatin, and poly-L-lysine films. *J Biomater Appl*, 2012. **26**(7): p. 791-809.
83. Kievit, F.M., et al., Chitosan-alginate 3D scaffolds as a mimic of the glioma tumor microenvironment. *Biomaterials*, 2010. **31**(22): p. 5903-10.
84. Wang, K., et al., Culture on 3D Chitosan-Hyaluronic Acid Scaffolds Enhances Stem Cell Marker Expression and Drug Resistance in Human Glioblastoma Cancer Stem Cells. *Adv Healthc Mater*, 2016. **5**(24): p. 3173-3181.
85. Wang, X., et al., Enrichment of glioma stem cell-like cells on 3D porous scaffolds composed of different extracellular matrix. *Biochem Biophys Res Commun*, 2018. **498**(4): p. 1052-1057.
86. Ahn, C.B., et al., Gallic Acid-g-Chitosan Modulates Inflammatory Responses in LPS-Stimulated RAW264.7 Cells Via NF-kappaB, AP-1, and MAPK Pathways. *Inflammation*, 2016. **39**(1): p. 366-374.
87. Chang, P.H., et al., Chitosan promotes cancer progression and stem cell properties in association with Wnt signaling in colon and hepatocellular carcinoma cells. *Sci Rep*, 2017. **8**: p. 45751.
88. Kadry, M.O., et al., Crosstalk between GSK-3, c-Fos, NFkappaB and TNF-alpha signaling pathways play an ambitious role in Chitosan Nanoparticles Cancer Therapy. *Toxicol Rep*, 2018. **5**: p. 723-727.
89. McConnell, D., et al., Do Anti-Oxidants Vitamin D3, Melatonin, and Alpha-Lipoic Acid Have Synergistic Effects with Temozolomide on Cultured Glioblastoma Cells? 2018. **5**(2): p. 58.
90. Wang, J., et al., Melatonin suppresses migration and invasion via inhibition of oxidative stress pathway in glioma cells. *J Pineal Res*, 2012. **53**(2): p. 180-7.
91. Khodagholi, F., et al., Chitosan prevents oxidative stress-induced amyloid β formation and cytotoxicity in NT2 neurons: involvement of transcription factors Nrf2 and NF- κ B. *Molecular and cellular biochemistry*, 2010. **337**(1-2): p. 39-51.
92. Ramachandran, R.K., et al., Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas. *PLoS One*, 2017. **12**(2): p. e0172234.

93. Zhang, H., et al., MMP-2 expression and correlation with pathology and MRI of glioma. *Oncol Lett*, 2019. **17**(2): p. 1826-1832.
94. Kong, C.-S., et al., Carboxymethylations of chitosan and chitin inhibit MMP expression and ROS scavenging in human fibrosarcoma cells. *Process Biochemistry*, 2010. **45**(2): p. 179-186.
95. Li, Z., et al., Apoptotic induction and anti-metastatic activity of eugenol encapsulated chitosan nanopolymer on rat glioma C6 cells via alleviating the MMP signaling pathway. *J Photochem Photobiol B*, 2020. **203**: p. 111773.
96. Johnstone, R.W., A.J. Frew, and M.J. Smyth, The TRAIL apoptotic pathway in cancer onset, progression and therapy. *Nature Reviews Cancer*, 2008. **8**(10): p. 782-798.
97. Ashkenazi, A., Targeting death and decoy receptors of the tumour-necrosis factor superfamily. *Nature Reviews Cancer*, 2002. **2**(6): p. 420-430.
98. Rieger, J., et al., APO2 ligand: a novel lethal weapon against malignant glioma? *FEBS letters*, 1998. **427**(1): p. 124-128.
99. Potu, H., et al., Tumor necrosis factor related apoptosis inducing ligand (TRAIL) regulates deubiquitinase USP5 in tumor cells. *Oncotarget*, 2019. **10**(56): p. 5745-5754.
100. Wang, K., et al., Nanoparticle-mediated target delivery of TRAIL as gene therapy for glioblastoma. *Advanced healthcare materials*, 2015. **4**(17): p. 2719-2726.

Legend to Figure:

Figure 1. Schematic representation of chitosan applications for culturing glioma cells and drugs delivery. (A) Studies reported that 3D chitosan scaffolds are more effective for culturing glioma cells compared to 2D monolayer cultures. These scaffolds provide a platform for drug screening and studying the biology of glioma cells. (B) Findings suggest that chitosan nanoparticles are potential targets for delivering glioma therapeutic drugs.

Journal Pre-proof




Figure 1